R. Weiss

发表

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

C. Shear, J. Alexander, D. Angiolillo, 2015, Journal of the American Heart Association.

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

J. Legg, C. Recknor, M. Geller, 2016, SpringerPlus.

Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group.

M. Brodsky, R. Weiss, R. Bellinger, 1994, American heart journal.

Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).

E. Duffield, C. Ballantyne, T. Moccetti, 2007, The American journal of cardiology.

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Robert Dufour, D. Gaudet, E. Stein, 2012, The Lancet.

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Jennifer G. Robinson, D. Gaudet, G. Watts, 2015, The Journal of clinical endocrinology and metabolism.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, JAMA.

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, Clinical cardiology.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

C. Ballantyne, E. Stein, P. Théroux, 2006, American heart journal.

hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.

K. Watson, G. Fonarow, B. Ansell, 2003, Heart disease.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.